Benchling Launches One-Click Ordering for Biopharma R&D with Twist Bioscience, Adaptyv, and Ginkgo Bioworks
Scientists can now design biological experiments, place orders with external lab partners, and receive structured results, without leaving Benchling
SAN FRANCISCO, May 6, 2026 /PRNewswire/ -- Benchling, the AI platform for biotech R&D, today announced the launch of direct ordering for biological materials and CRO services. This update integrates industry leaders Twist Bioscience for gene synthesis, antibody expression, binding, developability and other characterization services, Adaptyv for protein engineering services, and Ginkgo Bioworks for antibody developability into Benchling. Scientists can submit candidates, place orders, and receive results, returned as structured data linked to the original designs, without leaving their workflow. Each order stays connected to its full experimental context including in silico design, target, project history, and prior results, so that each experiment builds on prior work.
What this means for the biopharma industry
Scientists can generate a thousand antibody candidates computationally in an afternoon. But making and experimentally validating them takes far longer, often slowed by ordering materials, coordinating with CROs, and bringing results back into the experimental workflow. These steps slow validation and widen the gap between design and insight. By unifying the digital design layer with the physical execution layer, Benchling delivers a high-velocity feedback loop critical for AI-driven R&D. This integration ensures that every experiment feeds directly into the next, providing the structured data necessary to train and refine predictive models at scale.
"The lab needs to work differently if science is going to move at the pace AI enables, and that includes external labs," said Ashu Singhal, co-founder and president of Benchling. "Scientists should be able to design an experiment, order it without leaving their notebook, and have results flow back seamlessly to guide their next decision."
With Twist, this includes both data and physical goods, which are shipped directly to the lab and linked back to originating designs and project context.
"Through this integration with Benchling, we're making it seamless for researchers to order Twist genes, antibody expression, binding, developability and other characterization services directly from the notebook where they design their experiments. This removes friction between digital design and physical execution, accelerating the path from insight to result," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.
How it works
Design, evaluation, ordering, and tracking all happen in one continuous workflow in Benchling:
This workflow operates across the environment where scientists already work in Benchling, including notebooks for experimental execution, sequence editors for design, and registries for managing and ordering at scale.
Ordering partners
Part of a larger loop
Benchling's recent AI innovations connect the digital and physical layers of R&D so scientists can design experiments, execute them, and analyze results within a single system.
Availability
Ordering with Twist Bioscience for Gene Fragments and Adaptyv is available now for early access for all Benchling customers. Access is expanding to Ginkgo Bioworks later this year. Sign up and get access here
About Benchling
Benchling is the AI platform for biotech R&D, unifying scientific data and automating workflows to accelerate discovery and development. Trusted by more than 1,300 companies worldwide, from pioneering startups to global leaders like Merck, Moderna, and Sanofi, Benchling gives scientists a single place to capture, connect, and act on data across the entire R&D lifecycle. With Benchling AI, agents and models work directly inside scientific workflows, grounded in structured data. The result is faster teams, better molecules, and breakthroughs that reach the world sooner.
SOURCE Benchling